The long-term goal of the pioneering trial of iPSC-derived cells is to provide blood platelets to people undergoing cancer therapy, who need platelet transfusions to repair damaged tissues and prevent uncontrolled bleeding. Initially, however, platelets grown from iPSC will be given to healthy volunteers. Researchers in charge of the proposed trial, planned by Advanced Cell Technology (ACT) of Marlborough, Massachusetts, want to ensure that the cells are well tolerated before moving on to people with cancer and other blood-related conditions.

Read more: “2013 Smart Guide: 10 ideas that will shape the year”

If all goes to plan, 2013 should see the first human trial of “rewound” cells. These are produced by turning adult cells back to a stem cell state and then coaxing them into becoming another type of cell. It will mark a milestone in our ability to generate new tissue – and maybe whole organs – from people’s own cells.

If you are having a technical problem posting a comment, please contact technical support.

All comments should respect the New Scientist House Rules. If you think a particular comment breaks these rules then please use the “Report” link in that comment to report it to us.

Volunteers will be given platelets made from pre-existing stocks of iPSCs, but if the trial goes well, Lanza says they will create platelets from cancer patients’ own cells.

Some studies of iPSCs have suggested that they may have a higher risk of becoming cancerous. “Since platelets don’t have nuclei they can’t form tumours, which makes them ideal for the first iPSC clinical trial,” says Robert Lanza, chief medical officer at ACT.